Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
CYCCP's Cash to Debt is ranked higher than
88% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. CYCCP: No Debt )
CYCCP' s 10-Year Cash to Debt Range
Min: 1   Max: No Debt
Current: No Debt

Equity to Asset 0.79
CYCCP's Equity to Asset is ranked higher than
83% of the 772 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. CYCCP: 0.79 )
CYCCP' s 10-Year Equity to Asset Range
Min: -3.51   Max: 0.88
Current: 0.79

-3.51
0.88
Interest Coverage No Debt
CYCCP's Interest Coverage is ranked higher than
76% of the 447 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CYCCP: No Debt )
CYCCP' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: -6.14
M-Score: -1.50
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1526.03
CYCCP's Operating margin (%) is ranked higher than
55% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: -55.17 vs. CYCCP: -1526.03 )
CYCCP' s 10-Year Operating margin (%) Range
Min: -66250   Max: -1658.12
Current: -1526.03

-66250
-1658.12
Net-margin (%) -1341.47
CYCCP's Net-margin (%) is ranked higher than
55% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: -51.98 vs. CYCCP: -1341.47 )
CYCCP' s 10-Year Net-margin (%) Range
Min: -65040   Max: -936.62
Current: -1341.47

-65040
-936.62
ROE (%) -64.00
CYCCP's ROE (%) is ranked higher than
62% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -25.77 vs. CYCCP: -64.00 )
CYCCP' s 10-Year ROE (%) Range
Min: -147.62   Max: -42.99
Current: -64

-147.62
-42.99
ROA (%) -50.01
CYCCP's ROA (%) is ranked higher than
61% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -19.98 vs. CYCCP: -50.01 )
CYCCP' s 10-Year ROA (%) Range
Min: -106.85   Max: -34.56
Current: -50.01

-106.85
-34.56
ROC (Joel Greenblatt) (%) -8590.23
CYCCP's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -210.62 vs. CYCCP: -8590.23 )
CYCCP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -10204.73   Max: -503.45
Current: -8590.23

-10204.73
-503.45
Revenue Growth (%) 51.80
CYCCP's Revenue Growth (%) is ranked higher than
96% of the 653 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. CYCCP: 51.80 )
CYCCP' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 51.8
Current: 51.8

0
51.8
EBITDA Growth (%) -35.20
CYCCP's EBITDA Growth (%) is ranked higher than
59% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. CYCCP: -35.20 )
CYCCP' s 10-Year EBITDA Growth (%) Range
Min: -50.4   Max: 14.1
Current: -35.2

-50.4
14.1
EPS Growth (%) -27.80
CYCCP's EPS Growth (%) is ranked higher than
65% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. CYCCP: -27.80 )
CYCCP' s 10-Year EPS Growth (%) Range
Min: -50.8   Max: 19.3
Current: -27.8

-50.8
19.3
» CYCCP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with CYCCP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Cyclacel Pharmaceuticals Inc

SymbolPriceYieldDescription
CYCCP7.028.606% Convertible Exchangeable Preferred Stock

Ratios

vs
industry
vs
history
P/B 2.65
CYCCP's P/B is ranked higher than
82% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. CYCCP: 2.65 )
CYCCP' s 10-Year P/B Range
Min: 0.22   Max: 12.95
Current: 2.65

0.22
12.95
P/S 43.00
CYCCP's P/S is ranked higher than
56% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.61 vs. CYCCP: 43.00 )
CYCCP' s 10-Year P/S Range
Min: 6.13   Max: 1190
Current: 43

6.13
1190
EV-to-EBIT -2.18
CYCCP's EV-to-EBIT is ranked higher than
65% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CYCCP: -2.18 )
CYCCP' s 10-Year EV-to-EBIT Range
Min: -3.9   Max: 0.6
Current: -2.18

-3.9
0.6
Current Ratio 4.79
CYCCP's Current Ratio is ranked higher than
77% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. CYCCP: 4.79 )
CYCCP' s 10-Year Current Ratio Range
Min: 0.96   Max: 12.96
Current: 4.79

0.96
12.96
Quick Ratio 4.79
CYCCP's Quick Ratio is ranked higher than
78% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. CYCCP: 4.79 )
CYCCP' s 10-Year Quick Ratio Range
Min: 0.96   Max: 12.96
Current: 4.79

0.96
12.96

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 8.60
CYCCP's Dividend Yield is ranked lower than
327% of the 178 Companies
in the Global Biotechnology industry.

( Industry Median: 1.13 vs. CYCCP: 8.60 )
CYCCP' s 10-Year Dividend Yield Range
Min: 0   Max: 0
Current: 8.6

Yield on cost (5-Year) 8.60
CYCCP's Yield on cost (5-Year) is ranked lower than
318% of the 183 Companies
in the Global Biotechnology industry.

( Industry Median: 1.27 vs. CYCCP: 8.60 )
CYCCP' s 10-Year Yield on cost (5-Year) Range
Min: 0   Max: 0
Current: 8.6

Share Buyback Rate -41.00
CYCCP's Share Buyback Rate is ranked higher than
60% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. CYCCP: -41.00 )
CYCCP' s 10-Year Share Buyback Rate Range
Min: 5.7   Max: -144.4
Current: -41

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.05
CYCCP's Price/Net Cash is ranked higher than
95% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 125.18 vs. CYCCP: 3.05 )
CYCCP' s 10-Year Price/Net Cash Range
Min: 0.56   Max: 9.22
Current: 3.05

0.56
9.22
Price/Net Current Asset Value 2.89
CYCCP's Price/Net Current Asset Value is ranked higher than
95% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 57.00 vs. CYCCP: 2.89 )
CYCCP' s 10-Year Price/Net Current Asset Value Range
Min: 0.55   Max: 8.99
Current: 2.89

0.55
8.99
Price/Tangible Book 2.65
CYCCP's Price/Tangible Book is ranked higher than
90% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 8.79 vs. CYCCP: 2.65 )
CYCCP' s 10-Year Price/Tangible Book Range
Min: 0.42   Max: 5.95
Current: 2.65

0.42
5.95
Price/Median PS Value 0.39
CYCCP's Price/Median PS Value is ranked higher than
96% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. CYCCP: 0.39 )
CYCCP' s 10-Year Price/Median PS Value Range
Min: 0.07   Max: 9.18
Current: 0.39

0.07
9.18
Earnings Yield (Greenblatt) -45.90
CYCCP's Earnings Yield (Greenblatt) is ranked lower than
187% of the 312 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. CYCCP: -45.90 )
CYCCP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 166.5   Max: 20069.4
Current: -45.9

166.5
20069.4
Forward Rate of Return (Yacktman) -85.04
CYCCP's Forward Rate of Return (Yacktman) is ranked higher than
57% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: -9.72 vs. CYCCP: -85.04 )
CYCCP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1295.1   Max: -74.9
Current: -85.04

-1295.1
-74.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:UXI2.Germany
Cyclacel Pharmaceuticals, Inc., was founded in 1996, and is incorporated Delaware. The Company is a development-stage biopharmaceutical company engaged in the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. The Company develops and commercializes small-molecule drugs that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, particularly those of high unmet medical need. Cyclacel's clinical development priorities are focused on sapacitabine: Acute myeloid leukemia, Myelodysplastic syndromes, and Non-small cell lung cancer.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK